Navigation Links
FDA Grants Meridian Laboratories Pre-Ind Meeting for Captisol-Enabled Docetaxel in the Treatment of Cancer

CHICAGO, Oct. 11, 2012 /PRNewswire-iReach/ -- Buffalo Grove, Illinois-based specialty-oncology drug development company, Meridian Laboratories, Inc is pleased to announce that the US Food and Drug Administration (FDA) has granted Meridian's request for a Type B Pre-Investigational New Drug (pre-IND) meeting to discuss its plan to commence clinical trials of ML061 as a treatment for various cancer indications. The meeting is scheduled for January 23, 2012

Meridian's lead product, ML061, is an IP-protected reformulation of Taxotere in Captisol that eliminates Polysorbate-80 and could remove the associated "Black Box" warnings and precautions.  Meridian intends to seek approval with an abbreviated New Drug Application in the US with under SEC. 505(b)(2) [21 USC §355] New Drugs

Chairman Dr. William Zhao welcomed the response from the FDA. "We are pleased with this timely and positive response from the FDA. This is a significant step forward in the development of ML061." Meridian has assembled an accomplished biopharmaceutical development team including clinical and regulatory experts, Dr. G. Steven Geis and George Allen Hides. "Our proven team is already delivering outcomes." Dr. Geis, who is heading the clinical development of ML061, noted that Meridian Labs has a robust package of data to support regulatory submission through the US 505 (b)(2) regulatory pathway. "Following a successful pre-IND meeting, we expect to initiate a bioequivalence study in cancer patients in 2013."

About Meridian Labs

As the company's leading product, ML061 improves the formulation of Taxotere for cancer treatment, based on the same active ingredient docetaxel with a novel delivery method. By avoiding polysorbate 80 and ethanol, our objective is to show that ML061 improves the safety profile of Taxotere while maintaining its efficacy. We plan to bring the product to market as the top choice of chemotherapy for various cancer indications.

About AmeriTech Advisors

AmeriTech Advisors is an investment bank dedicated to providing capital raising and strategic advisory services to growth companies in the technology, medtech, and financial sectors with market capitalizations of between $25 million and $500 million. Their bankers have 20 years' experience at major global investment banks and as senior managers at public companies with experience executing successful transactions. Their goal is to build mutually beneficial relationships between our emerging growth company clients, technology and medtech/pharma partners, and their network of investors


Dan D'Agostino

Managing Director, Investment Banking

AmeriTech Advisors


Media Contact: william zhao, Meridian Laboratories, Inc, 847-275-5923,

News distributed by PR Newswire iReach:

SOURCE Meridian Laboratories, Inc
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. UNH labs receive 2 NSF grants totalling $1.35m for research instruments
2. Columbia awarded 1 of first Provocative Questions grants from NCI
3. New NIH/NHGRI grants to harness nanoscale technologies to cut DNA sequencing costs
4. 2 UNC faculty receive Autism Centers of Excellence grants for new research
5. 6 NARSAD Young Investigator Grants awarded to CAMH
6. American Health Assistance Foundation announces grants to advance promising vision research
7. Grants add to Northwestern-Qatar partnership
8. Bay Area PV Consortium announces $7.5 million in grants to lower the cost of large-scale solar
9. Scientist wins $3 million renewal of one of longest-running NIH grants to Scripps Research
10. Millennium Laboratories Launches New Assay to Detect Use of Kratom
11. 2012 ACMG Foundation/Signature Genomic Laboratories Travel Award winner announced
Post Your Comments:
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/9/2016)...  Perkotek an innovation leader in attendance control systems is proud to announce the ... employers to make sure the right employees are actually signing in, and to even ... ... ... ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Researchers at ... most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the ... read it now. , Diagnostic biomarkers are signposts in the blood, lung fluid ...
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
Breaking Biology Technology: